News

Posted: 2015-01-01

A recent preliminary retrospective study of patients on active surveillance has demonstrated a technique to enhance the identification of patients requiring definitive treatment.

Posted: 2014-11-19

November 18, 2014 - Prostate Cancer Canada has awarded a third Translation Acceleration Grant under their program TAG2: Novel Therapeutics for Advanced Disease. This funding is for groups studying novel therapeutics and treatment options for metastatic and castrate-resistant prostate cancer, for projects aimed at eliminating advanced disease from affected men.

Posted: 2014-11-18

The latest issue of Vancouver Coastal Health Research Institute News includes a discussion with Dr. Ralph Buttyan on his Prostate Cancer Canada - Movember funded team research program. The article "How Movember’s moustaches are taking prostate cancer down" is available here.

Posted: 2014-11-14

A multinational study lead by Dr. Rob Bristow and including Dr. Colin Collins of the VPC was published in The Lancet Oncology and was written up in The Globe and Mail.

Posted: 2014-11-03

November 3, 2014 - Dr. Ralph Buttyan was on Breakfast Television Vancouver this morning, discussing his Movember-funded team grant. The interview also touches on the current PSA testing controversy.  Watch the whole interview here, and learn more about the inaugural team grant here.

Posted: 2014-10-30

This week, the Canadian Task Force on Preventive Health Care recommended not using PSA as a screening test for prostate cancer.

Posted: 2014-09-26

September 26, 2014 - Prostate Cancer Canada today annouced the results of their funding decision in their Translation Acceleration Grant competition TAG2: Novel Therapeutics for Advanced Disease.  This funding is for groups studying novel therapeutics and treatment options for metastatic and castrate-resistant prostate cancer, for  projects aimed at eliminating advanced disease from affected men.

Posted: 2014-09-12

SHENZHEN, China and VANCOUVER, British Columbia, September 12, 2014 – BGI, the world’s largest genomics organization, based in China, and The Vancouver Prostate Centre (VPC), a global leader in translational research in cancer, today announced the establishment of the BGI-VPC Joint Research Laboratory, a sequencing and translational research facility, to jointly discover and advance basic and translational programs in oncology, including precision oncology.

Posted: 2014-08-26

Sequencing RNA, not just DNA, could help doctors predict how prostate cancer tumors will respond to treatment, according to research published in the open access journalGenome Biology. Because a tumor’s RNA shows the real time changes a treatment is causing, the authors think this could be a useful tool to aid diagnosis and predict which treatment will most benefit individual cancer patients.

Posted: 2014-08-25

With the awarding of $14.5M under the Canadian government’s Networks of Centres of Excellence (Centres of Excellence for Commercialization and Research (CECR)) Program, as announced earlier this morning by the Honourable Ed Holder, Minister of State for Science and Technology, Accel-Rx - Canada’s Health Sciences Accelerator is officially launched.

A World Class Centre

The Vancouver Prostate Centre (VPC) has a track record of success that has earned it a reputation as one of the world’s most respected cancer facilities. It is a National Centre of Excellence and a designated Centre of Excellence for Commercialization and Research.

Employment

Work at the Vancouver Prostate Centre

Tuesday, November 27, 2018

An innovative new study advances personalized medicine for prostate cancer patients

Drs Chi and Wyatt
Tuesday, October 23, 2018

Three researchers receive Prostate Cancer Canada & Movember Foundation grants for biomarker development